Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

Also called NCT06161844

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 506 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06161844
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06161844. Randomized; no masking; primary purpose treatment. Start 2024-02-23 (actual); primary completion 2025-05-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
semaglutide injection (HD1916)
Intervention (Drug)
Ozempic®
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06161844
Content hash
b2fbcd8a5896459fee579997a533ae5135f7ffded37c4537d6498326f50bdaf5